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222a Monday, February 22, 2010Mitochondria are the energy producing organelles of eukaryotic cells. Owing
to their endosymbiotic evolutionary history, they contain their own genome
(mtDNA) that encodes for thirteen proteins essential for ATP production.
In mammalian cells, multiple mtDNAs are compacted into protein-DNA com-
plexes called "nucleoids". A major component of these nucleoids is the mito-
chondrial transcription factor A (TFAM), a member of the high mobility group
(HMG) family of proteins. This abundant protein binds DNA with little
sequence specificity, and is able to coat the entire mtDNAmolecule. It not only
serves a role in mtDNA packaging, but is also required for mitochondrial
transcription. At this point, dynamics of the TFAM-DNA interaction remain
unclear.
Experiments on single DNA molecules offer a very direct way to study TFAM
dynamics. Tethered Particle Motion (TPM) experiments show that the system
quickly equilibrates with the buffer, and that the end-to-end distance of the
DNA decreases upon TFAM binding. Manipulations of single DNA molecules
with two optical traps offer an explanation: TFAM decreases the DNA’s stiff-
ness (persistence length). A possible molecular mechanism for this decrease is
that TFAM introduces bends in the DNA.
Adding single-molecule fluorescence to the dual optical trap illuminates
TFAM’s binding behavior. Literally seeing TFAM on the DNA, we can
derive on- and off-rates, and determine that TFAM does not bind coopera-
tively. Interestingly and seemingly unrelated to its role in DNA organiza-
tion, we also observe that TFAM can rapidly bind single-stranded DNA
(ssDNA), but not when the ssDNA is under tension. The physiological
function of TFAM binding to ssDNA could be related to its regulation of
transcription.Symposium 9: Biophysics of the Failing Heart
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on Cardiac Myosin Function?
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Familial hypertrophic cardiomyopathy (FHC) is a clinically and genetically
heterogeneous disease which is a major cause of heart failure. The landmark
discovery that a point mutation at residue 403 (R403Q) in the b-myosin heavy
chain (MHC) can cause a lethal form of FHC was made in 1990, but the effect
of this mutation on the functional properties of human cardiac myosin remains
poorly understood. One problem has been that the prevalent mouse model for
FHC expresses predominantly a-MHC. The b-MHC, however, is the predom-
inant isoform in the ventricles of all larger mammals. Even though the a- and
b-MHC share > 90 % sequence identity, they differ ~ 2-fold in enzymatic and
mechanical properties, raising the possibility that the effect of a disease mu-
tation may depend on the isoform backbone. To address this question we used
a transgenic mouse model in which the endogenous a-MHC was replaced
with transgenically encoded b-MHC. A His-tag was cloned at the N-terminus
of a- and b-MHC, along with the R403Q mutation, to facilitate isolation of
myosin or its head subfragment-1 (S1).We find that the steady-state ATPase
activity and in vitro motility of mouse a-MHC is enhanced by the R403Q mu-
tation, as reported previously, but the R403Q mutation in a b-MHC back-
ground shows a slight reduction in activity. A more in-depth analysis of the
R403Q phenotype is being undertaken by stopped-flow kinetics to measure
the nucleotide turnover in these mutant S1 isoforms. In order to determine
the extent of species-dependent differences, we are comparing the functional
properties of b-cardiac myosin in the mouse with those in the rabbit, a model
system which more closely resembles humans in protein composition and dis-
ease phenotypes.
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Myosin binding protein C (MyBP-C) is a thick filament accessory protein that
has both structural and regulatory roles in striated muscle contraction. We are
studying the roles of the cardiac isoform of MyBP-C in mouse models in
which the cMyBP-C gene has been disrupted, resulting in ablation of the pro-
tein, and in mice expressing mutant protein in which residues that are phos-
phorylated in vivo by PKA have been replaced with ala or asp. Ablation of
cMyBP-C results in a cardiac phenotype similar to many inherited cardiomy-
opathies in humans, i.e., septal hypertrophy, increased arrhythmic activity,
and systolic and diastolic dysfunction. Studies of isolated myocytes from
wild-type and null mice suggest that cMyBP-C regulates the kinetics ofcross-bridge interaction with actin, a mechanism that is lost in the null mouse.
Studies of myocytes from mouse lines expressing phosphorylation mutants of
cMyBP-C indicate that PKA stimulation of contraction kinetics in myocar-
dium is in large part due to phosphorylation of cMyBP-C, which appears to
relieve a structural constraint on myosin and increases the likelihood of my-
osin binding to actin. Living myocardium expressing non-phosphorylatable
cMyBP-C was found to exhibit depressed twitch force-frequency relationships
and reductions in both frequency-dependent and b-agonist- induced accelera-
tion of relaxation. These results can be explained by a model in which
cMyBP-C phosphorylation accelerates cross-bridge interaction kinetics in
wild-type myocardium, a regulatory mechanism that is lost in myocardium ex-
pressing the non-phosphorylatable mutant cMyBP-C. Supported by NIH R01
HL082900 and P01 HL094291.
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Familial cardiomyopathies are commonly linked to missense mutations, dele-
tions or truncations in sarcomeric, cytoskeletal, or intermediate filament
proteins and give rise to hypertrophic cardiomyopathy (HCM), dilated cardio-
myopathy (DCM) or restrictive cardiomyopathy. Although in the last two de-
cades much information about the pathophysiology of genetically linked
HCM and DCM has been provided by studies using transgenic animal models,
there is still no therapy to prevent the development of the disease and increase
survival in patients with HCM or DCM. Our emphasis here is on development
of new therapies for treatment of HCM and DCM linked to mutations in thin
filament proteins that are associated with increased and decreased myofila-
ment sensitivity to Ca2þ respectively. We hypothesize that direct modifica-
tions of myofilament Ca2þ sensitivity and/or alteration in Ca2þ fluxes can
serve as new therapeutic targets. Therefore if 1) HCM is associated with in-
creased myofilament sensitivity to Ca2þ, interventions that desensitize the
myofilament to Ca2þ may serve as potential new therapeutic targets and 2)
DCM is associated with decreased myofilament sensitivity to Ca2þ, interven-
tions that sensitize the myofilament to Ca2þ may serve as potential new ther-
apeutic targets. There are several possible targets within myofilament proteins
for altering myofilament Ca2þ sensitivity, in particular troponin I. Alterations
in Ca2þ regulation by modification of sarcoplasmic reticulum Ca-ATPase
(Serca2) or phospholamban levels are additional potential targets for HCM
and DCM.Minisymposium 2: Nanomedicine: Biophysical
Approaches to Clinical Problems at the
Nanoscale
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TRiC is a eukaryotic chaperonin essential for de novo folding of ~10% newly
synthesized cytosolic proteins, many of which cannot be folded by other cel-
lular chaperones. Unlike prokaryotic and archael chaperonins, each of its two
rings consists of eight unique, but similar subunits. Using single particle cryo-
EM, we determined the mammalian TRiC structure without any symmetry im-
position at 4.7 A˚ resolution, which is the highest resolution asymmetric cryo-
EM reconstruction to date. An analysis of this map allowed us to elucidate the
relative orientation of the two rings and the two-fold symmetry axis location
between them. A subsequent two-fold symmetrized map yielded a 4.0 A˚ struc-
ture, in which a large fraction of side chains and structural elements including
loops and insertions appear as visible densities. These features permitted
unambiguous identification of all eight individual subunits, despite their sim-
ilarity. A Ca backbone model of the entire TRiC complex was subsequently
refined from initial homology models against the cryo-EM density based on
our subunit identification. A refined all-atom model for a single subunit
